Opexa’s Tcelna immunotherapy is advancing in Phase IIb studies in secondary progressive MS (SPMS), with data expected in H216. The firm is fully funded to Phase II data which, if positive, could sharply increase investor and stakeholder interest. Merck KGaA has an option to in-license Tcelna in MS. Opexa is also developing OPX-212 in neuromyelitis optica (NMO), a rare autoimmune disorder leading to vision loss and paralysis. Opexa plans to file an IND and start a Phase I/II study in H11
30 Nov 2015
Personalized immunotherapy for MS
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Personalized immunotherapy for MS
- Published:
30 Nov 2015 - Author:
- Pages:
Opexa’s Tcelna immunotherapy is advancing in Phase IIb studies in secondary progressive MS (SPMS), with data expected in H216. The firm is fully funded to Phase II data which, if positive, could sharply increase investor and stakeholder interest. Merck KGaA has an option to in-license Tcelna in MS. Opexa is also developing OPX-212 in neuromyelitis optica (NMO), a rare autoimmune disorder leading to vision loss and paralysis. Opexa plans to file an IND and start a Phase I/II study in H11